Vivaxim Dosage/Direction for Use

Posology: The recommended dose is 1 ml of mixed vaccine.
Initial protection is obtained after a single injection of VIVAXIM. Protective antibody levels are only obtained 14 days after administration of the vaccine.
In order to obtain long term protection against hepatitis A virus, a booster dose of inactivated hepatitis A virus must be given 6 to 12 months later. Anti HAV antibodies persist for several years (at least 10 Years) after the booster.
In subjects who have received one dose of VIVAXIM: Either one dose of monovalent hepatitis A vaccine should be administered within 36 months and preferably within 6 to 12 months (see Pharmacology: Pharmacodynamics under Actions).
Or, if protection against typhoid is still required, a second dose of VIVAXIM may be administered provided that approximately 36 months have elapsed since the first dose.
In subjects who have received one dose of monovalent hepatitis A vaccine: VIVAXIM may be used to provide the second dose (booster) of hepatitis A vaccine, if protection against typhoid fever is also desirable. It should then be administered within 36 months of the hepatitis A vaccine injection and preferably within 6 to 12 months.
As this vaccine has not been evaluated in subjects aged under 16 years, it is not recommended to use in this age group.
Method of administration: VIVAXIM should be administered by slow intramuscular injection in the deltoid region.
VIVAXIM must not be administered intravascularly.
VIVAXIM should not be administered into the buttock due to the varying amount of fatty tissue in this region of the body, nor by the intradermal route since these methods of administration may induce a weaker immune response.
VIVAXIM may be administered by the subcutaneous route in patients with thrombocytopenia or in patients at risk of haemorrhage.
For instructions for preparation of the medicinal product before administration, see Special precautions for disposal and other handling under Cautions for Usage.